Ipriflavone improves bone density and biomechanical properties of adult male rat bones.
To assess the potential impact of ipriflavone on the biomechanical properties and mineral composition of bone, we administered two doses (200 or 400 mg/kg bw) of the drug orally to adult male rats for 1 month. Bone biomechanics were evaluated by vibration damping, an index of strain energy loss, and impact strength (the amount of energy required to fracture after a single impact). At the higher dose, ipriflavone significantly decreased vibration damping of rat femurs by 23.0 +/- 9.8% compared with control, vehicle-treated animals, suggesting a higher capacity to withstand dynamic stress. This result was confirmed by the impact strength studies showing that a higher energy (49.6 +/- 21.3% above control) was required to fracture femurs of rat treated with 400 mg/kg bw ipriflavone. The high dose of ipriflavone increased bone mineral density, assessed by both volume displacement and ash analysis (4.2% and 2.5% above controls, respectively). The relative content of calcium, phosphorus, and magnesium in the ashes was not different among the treated and untreated groups, indicating that no gross abnormalities in mineral composition of bone occurred after ipriflavone administration. Similarly, there were no differences in serum calcium and magnesium levels between treated and control animals at the end of the study, whereas lower circulating phosphorus levels were detected in the latter. Ipriflavone treatment was not associated with significant changes in serum alkaline phosphatase nor type I collagen telopeptide levels, two markers of bone turnover. In summary, 1-month treatment with ipriflavone increased bone density and improved the biomechanical properties of adult rat male bones without altering mineral composition.(ABSTRACT TRUNCATED AT 250 WORDS)
Civitelli
R
R
Department of Medicine, Washington University School of Medicine, Jewish Hospital of St. Louis, Missouri 63110, USA.
Abbasi-Jarhomi
S H
SH
Halstead
L R
LR
Dimarogonas
A
A
D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects; D002118:Calcium / Q000097:blood; D005264:Femoral Fractures / Q000503:physiopathology / Q000517:prevention & control*; D005269:Femur / Q000187:drug effects* / Q000502:physiology; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008962:Models, Theoretical; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy; D010758:Phosphorus / Q000097:blood; D011863:Radioimmunoassay; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013314:Stress, Mechanical
D015415:Biomarkers; D007529:Isoflavones; D010758:Phosphorus; C018986:ipriflavone; D000469:Alkaline Phosphatase; D002118:Calcium